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Loh et al. identify the WNT co-receptor
LRP5 as a regulator of human body fat
distribution, an independent predictor of
diabetes and cardiovascular disease risk.
Studying LRP5 gene variant carriers and
human fat progenitors, they show that
LRP5 differentially modulates regional
adipose progenitor biology by titrating
WNT/b-catenin signaling dosage.
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Common variants in WNT pathway genes have been
associated with bone mass and fat distribution, the
latter predicting diabetes and cardiovascular dis-
ease risk. Rare mutations in the WNT co-receptors
LRP5 and LRP6 are similarly associated with bone
and cardiometabolic disorders. We investigated the
role of LRP5 in human adipose tissue. Subjects
with gain-of-function LRP5 mutations and high
bone mass had enhanced lower-body fat accumula-
tion. Reciprocally, a low bone mineral density-
associated common LRP5 allele correlated with
increased abdominal adiposity. Ex vivo LRP5
expression was higher in abdominal versus gluteal
adipocyte progenitors. Equivalent knockdown of
LRP5 in both progenitor types dose-dependently
impaired b-catenin signaling and led to distinct bio-
logical outcomes: diminished gluteal and enhanced
abdominal adipogenesis. These data highlight how
depot differences in WNT/b-catenin pathway activity
modulate human fat distribution via effects on adipo-
cyte progenitor biology. They also identify LRP5 as a
potential pharmacologic target for the treatment of
cardiometabolic disorders.
INTRODUCTION
Obesity is associated with the development of insulin resis-
tance, linked to the pathogenesis of type 2 diabetes (T2D)
and cardiovascular disease (CVD). Nonetheless, adverse meta-
bolic sequelae are not uniformly observed in obese individuals.
While subjects with abdominal obesity display an increased
prevalence of CVD, similarly overweight individuals with gluteo-
femoral fat distribution are protected from cardiometabolic dis-262 Cell Metabolism 21, 262–272, February 3, 2015 ª2015 The Authoorders (Yusuf et al., 2005). Consistent with epidemiologic find-
ings, physiological studies have shown that the gluteofemoral
white adipose tissue (WAT) depot displays differential fatty
acid (FA) handling compared to the subcutaneous (SC) abdom-
inal WAT depot (Jensen, 2008; Karpe and Pinnick, 2014). By
favoring the long-term storage of FAs, gluteofemoral fat may
protect skeletal muscle from ectopic lipid accumulation and lip-
otoxicity, which triggers insulin resistance (Schenk et al., 2008).
Gluteofemoral fat may also contribute to improved metabolic
risk by secreting a more beneficial adipocytokine profile than
SC abdominal and visceral fat (Fontana et al., 2007; Turer
et al., 2011). Adipose-derived hormones and cytokines directly
modulate systemic insulin sensitivity (Qatanani and Lazar,
2007).
WAT expands by an increase in adipocyte number (hyperpla-
sia) and size (hypertrophy) (Spalding et al., 2008; Tchoukalova
et al., 2010). Adipocytes derive from mesenchymal stem cells
(MSCs) and preadipocytes that reside in the stromovascular
fraction of WAT. Several clinical and experimental studies indi-
cate that discrete fat depots arise from distinct precursors with
inherently different proliferative and adipogenic properties (Billon
and Dani, 2012; Semple et al., 2011; Tchkonia et al., 2006). It is
further postulated that developmental pathways play a key role
in establishing the distinct identities of adipose progenitors
from separate locations and thus in determining (1) the relative
size of fat depots, by determining adipocyte number (and size)
within each depot, and (2) the function of WAT depots, by modu-
lating expression of adipogenic genes and their downstream tar-
gets. Consistent with this hypothesis, stromovascular cells
(SVCs) isolated from discrete fat depots exhibit distinct develop-
mental gene expression profiles (Gesta et al., 2006; Tchkonia
et al., 2007). Furthermore, in a genome-wide association study
(GWAS) meta-analysis, 4 of the 13 identified loci associated with
bodymass index (BMI)-adjustedwaist-to-hip ratio (WHR), amea-
sure of body fat distribution, mapped in or near developmental
genes (Heid et al., 2010). Notably two of these, RSPO3 and
ZNRF3, constitute WNT signaling modulators. A locus near
RSPO3, distinct from theWHR-associatedsignal,wasalso shownrs
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Cell Mto be associated with bone mineral density (BMD) at genome-
wide significance (Duncan et al., 2011; Estrada et al., 2012).
WNTs are a family of 19 secreted glycoproteins acting locally
via multiple pathways to regulate adult tissue homeostasis
(Clevers and Nusse, 2012). In the b-catenin (‘‘canonical’’)
cascade, WNT binding to Frizzled (FZD) receptors and low-den-
sity lipoprotein receptor-related protein (LRP) 5/6 co-receptors
leads to nuclear accumulation of the transcriptional co-activator
b-catenin, which, paired with LEF/TCF transcription factors,
dose-dependently modulates (generally activates) WNT target
gene expression. WNTs also signal through ‘‘non-canonical’’
pathways. In the planar cell polarity (PCP) pathway,WNT binding
to FZD activates JNK and stimulates AP1-dependent transcrip-
tion. In the WNT/Ca2+ pathway, WNT/FZD interaction triggers
intracellular Ca2+ release and calmodulin-dependent protein
kinase-2A (CAMK2A) activation. Canonical and non-canonical
pathways are thought to be mutually antagonistic (Grumolato
et al., 2010; Weidinger and Moon, 2003).
WNT signaling is a key regulator of MSC biology (Christodou-
lides et al., 2009; Krishnan et al., 2006). Canonical signaling, the
best-studied pathway, which critically relies on LRP5 and LRP6
co-receptors for activation, has been shown to repress adipo-
genesis and stimulate osteoblastogenesis. Accordingly, patients
carrying rare gain-of-function (GoF) LRP5mutations exhibit high
bone mass (HBM) (Boyden et al., 2002; Little et al., 2002). Recip-
rocally, rare loss-of-function (LoF) LRP5 mutations lead to oste-
oporosis (Ai et al., 2005; Gong et al., 2001), which, in a study of 12
affected probands from two families, was coupled with an
increased prevalence of T2D (Saarinen et al., 2010). Finally,
rare inactivating missense mutations in LRP6 result in autosomal
dominant CVD, features of the metabolic syndrome, and osteo-
porosis (Mani et al., 2007; Singh et al., 2013). Prompted by these
and the aforementioned GWAS findings (Heid et al., 2010), we
sought to determine the role of LRP5 in human WAT biology
and fat distribution. Our interest in LRP5 was also stimulated
by preliminary analyses showing that it was differentially ex-
pressed between SC abdominal and gluteal SVCs. Furthermore,
WAT LRP5 mRNA levels correlated with measures of regional
adiposity and systemic insulin sensitivity. Herein we demon-
strate that LRP5-driven b-catenin signaling regulates adipose
progenitor proliferation and differentiation in a dose- and
depot-specific manner, thereby modulating human body fat
distribution.
RESULTS
HBM-Causing LRP5 Mutations Are Associated with
Lower-Body Fat Accumulation
We examined the adipose and metabolic phenotype of three
pedigrees with extreme HBM secondary to rare heterozygous
GoF LRP5 mutations. Compared to age-, gender-, and BMI-
matched Oxford Biobank (OBB) controls, HBM LRP5 mutation
carriers had an increased amount of lower-body fat as deter-
mined by whole-body dual energy X-ray absorptiometry (DXA).
In particular, all overweight/obese (BMI R 25) HBM subjects
with LRP5 mutations (n = 5 of 6 individuals in total; S1–S3, S5,
S6) had a higher tissue percent fat specifically in their legs
(Table 1). Furthermore, all affected individuals displayed lower
android/leg, android/total, and central/peripheral fat mass ratiosetabolism 21, 262–272, February 3, 2015 ª2015 The Authors 263
Table 2. Comparison of Anthropometry and DXA-Derived
Measures of Body Fat Distribution of HBM Subjects With and
Without LRP5 Gain-of-Function Mutations, Matched for Age,
Gender, and BMI
LRP5 HBM
(n = 6)
Non-LRP5 HBM
(n = 18)
Mean ± SD Mean (95% CI)
Age (years) 43.0 ± 14.5 41.9 (31.0, 52.7)
BMI (kg/m2) 27.7 ± 4.3 27.7 (25.5, 29.9)
Tissue legs, % fat 39.5 ± 11.8 36.3 (30.3, 42.2)
Tissue android, % fat 37.6 ± 14.7 46.8 (40.3, 53.3)a
Android:leg fat ratio (%) 19.0 ± 4.8 29.5 (26.5, 32.4)b
Android:total fat ratio (%) 7.1 ± 1.6 9.1 (8.4, 9.7)b
Central:peripheral fat mass
ratio (g/g)
15.0 ± 3.9 22.0 (19.9, 24.1)b
LRP5 HBM subjects (Tables 1 and S2) were matched with non-LRP5
HBM subjects on age (within 6 years), sex, and BMI (kg/m2), based on
radius matching with a ratio 3:1, using a multi-level regression model
clustering by match set. HBM, high bone mass; BMI, body mass index;
CI, confidence interval. See also Table S1.
ap < 0.05.
bp% 0.001.
Table 3. Association Studies of the BMD-Associated LRP5 SNP
Rs599083 and DXA-Derived Measures of Body Fat Distribution of
Subjects from the Oxford Biobank
Rs599083
Adjusted for age,
gender, and BMI
Adjusted for age,
gender, BMI, and BMD
Trait p value b n p value b n
Tissue leg,
% fat
0.4 0.007 3,289 1 0.002 3,289
Tissue android,
% fat
0.004a 0.033 3,289 0.02a 0.027 3,289
Android:leg fat
ratio (%)
0.008a 0.028 3,289 0.02a 0.025 3,289
Android:total fat
ratio (%)
0.006a 0.031 3,289 0.01a 0.027 3,289
Central:peripheral
ratio (g/g)
0.007 a 0.028 3,289 0.02a 0.024 3,289
BMD (g/cm2) 9 3 105a 0.058 3,289 – – –
Effect allele: guanine nucleotide. Effect allele frequency: 0.34. BMD, bone
mineral density; p value, empirical p value; b, standardized beta value; n,
number of subjects. Data are from 1,438men and 1,851 women. See also
Tables S3–S5 and Figure S2.
aSignificant p values.(Table 1). This adipose phenotype was not driven by the HBM, as
HBM LRP5 mutation carriers had a decreased upper-to-lower-
body fat ratio even when compared with matched non-LRP5
HBM cases (n = 18) (Table 2). Similar results were obtained
when comparing age-, gender-, and BMI-adjusted DXA data
from LRP5 HBM cases versus the rest of the (non-LRP5) HBM
cohort (n = 134) (Table S1). LRP5 HBM individuals also exhibited
enhanced insulin sensitivity as determined by lower HOMA-IR
and fasting insulin levels relative to OBB controls (Tables 1 and
S2). One exception was subject S2 (68 years old), whom we
were able to compare only with 49–50 year old gender- and
BMI-matched controls. Finally, ex vivo gene expression analyses
of fractionated SC adipose cells revealed lower inflammatory
gene transcript levels in LRP5 HBM individuals (n = 4; subjects
S1, S4–S6) versus OBB controls (n = 24–25) (Figure S1A). We
conclude that rare, GoF LRP5 mutations are associated with
enhanced lower-body fat accumulation, a favorable metabolic
profile, and reduced WAT inflammation.
A Low BMD-Associated Allele in LRP5 Correlates with
Upper-Body Fat Accumulation
To further investigate the role of LRP5 in regulating regional
adiposity, we explored the association between a common
LRP5 single nucleotide polymorphism (SNP) and DXA-derived
measures of fat distribution in 3,289 OBB volunteers.
Rs599083 is an intronic SNP shown to be significantly associ-
ated with lumbar spine BMD in a GWAS meta-analysis (Rivade-
neira et al., 2009). Of note, rs599083 showedmodest evidence of
association with fat distribution within the OBB cohort (Table 3).
Specifically, the low BMD-associated minor allele at this locus
correlated with increased age-, gender-, and BMI-adjusted
android tissue percent fat and android/total and central/periph-
eral fat mass ratios. These associations were attenuated
following adjustment for BMD, in keeping with rs599083 being264 Cell Metabolism 21, 262–272, February 3, 2015 ª2015 The Authoan overlapping signal for bone and fat traits (Table 3). Based
on the established association between LoF LRP5 mutations
and osteoporosis (Ai et al., 2005; Gong et al., 2001), we presume
that this allele is associated with reduced LRP5 function, which,
according to gene expression analyses from 37 OBB subjects
(Figure S2A) and eQTL data from the MuTHER consortium
(http://www.muther.ac.uk), is not driven by changes in adipose
LRP5 mRNA levels. We also undertook histological analyses of
SC abdominal WAT from 18 overweight and obese individuals.
Subject characteristics are shown in Table S3. These revealed
that adipocyte numbers in android fat tended to be lower in car-
riers of the low BMD-associated allele at rs599083 (GG, GT)
versus homozygous carriers of the common allele (TT) (p =
0.05). This effect was primarily due to a reduction in small adipo-
cytes (Figures S2B and S2C). No associations between
rs599083 and anthropometric measures of fat distribution were
identified within the OBB (Table S4). Nonetheless, and consis-
tent with our findings, this SNP was weakly associated with
BMI-adjusted waist circumference (WC) in females (p = 0.001
for association, b = 0.016 for theminor allele) in the publicly avail-
able sex-stratified GIANT data set (Randall et al., 2013). It should
be noted that associations between waist and hip circumfer-
ences and the respective regional fat masses (android and gy-
noid) within the OBB had rho values of 0.5 (Table S5). We
conclude that, mirroring the effects of rare GoF LRP5mutations,
a common LRP5 allele that is presumably associated with
reduced LRP5 function correlates with modestly increased up-
per-body fat accumulation.LRP5 Is More Highly Expressed in Abdominal Than
Gluteal Adipose Progenitors
In order to gain mechanistic insights into the effects of LRP5 on
fat distribution, we examined the LRP5 gene expression patternrs
Figure 1. LRP5 Expression in Human SC
Abdominal, Gluteal, and Visceral WAT
(A and B) LRP5 mRNA levels in (A) paired SC
abdominal (Abdo) and gluteal (Glut) fat biopsies
from lean andobese subjects (n=20/group) and (B)
paired SC abdominal and visceral fat biopsies from
16 individuals undergoing surgery. n = 7 women
(age 43.6 ± 15.1 years [range 21.2–61]; BMI 30.0 ±
9.1 kg/m2 [range 19.1–42]) and 9 men (age 63.9 ±
9.3 years [range 48–76]; BMI 26.5 ± 5 kg/m2 [range
18.9–33.7]). Age and BMI are means ± SD.
(C) RSPO3 mRNA levels in paired visceral versus
SCabdominal fat (n =16) andSCabdominal versus
gluteal fat (n = 20).
(D) LRP5mRNA levels in culturedSVCs (n = 25) and
mature adipocytes (ADS) (n = 24).
(E) Western blot and protein densitometry of LRP5
in immortalized (im) and primary (n = 5 pairs) SVCs
from healthy subjects. A, abdominal; G, gluteal.
(F) LRP5 mRNA levels in differentiating primary
abdominal and gluteal SVCs (n = 5 pairs).
(G)ComparisonsofLRP5mRNA levels inpairedSC
abdominal and gluteal WAT from women with gy-
noid (WC < 80 cm, n = 23) versus android (WCR
80 cm, n = 24) fat distribution.
qRT-PCR data were normalized to PGK1 and PPIA (A–C and G) and to 18S (D and F). *p < 0.05, **p < 0.01, ***p < 0.001, corrected for multiple testing.
Histogram data are means ± SEM. See also Tables S6, S7, and S8.in paired SC abdominal and gluteal fat from 20 lean and 20 obese
OBB volunteers (Table S6). LRP5 expression was identical in the
two depots, albeit lower in obese versus lean subjects (Fig-
ure 1A). We also compared LRP5 gene expression in paired
SC abdominal and visceral fat from 16 subjects undergoing sur-
gery. LRP5 mRNA levels were higher in SC abdominal WAT, in
contrast toRSPO3 gene expression, whichwas higher in visceral
versus SC fat (Figures 1B and 1C). We next determined the
expression of LRP5 in fractionated SC abdominal and gluteal
WAT (Figure 1D). LRP5 gene expression was higher in mature
adipocytes compared with SVCs from both depots. No differ-
ence in LRP5 transcript levels was observed between abdominal
and gluteal adipocytes. In contrast, LRP5 expression was signif-
icantly higher in abdominal versus gluteal SVCs (p = 4 3 106,
with Bonferroni correction). We corroborated this finding by
demonstrating higher abdominal LRP5 protein level in five inde-
pendent pairs of primary and one pair of immortalized (see
below) SVCs (Figure 1E). Finally, we examined the LRP5 gene
expression profile in differentiating SVCs from a further five sub-
jects. LRP5mRNA levels were higher in undifferentiated abdom-
inal versus gluteal SVCs but, following induction of adipogene-
sis, became indistinguishable between abdominal and gluteal
adipocytes (Figure 1F). In summary, LRP5 is more highly ex-
pressed in SC versus visceral fat. Furthermore, when comparing
SCdepots, LRP5mRNA and protein levels are specifically higher
in abdominal compared with gluteal adipose progenitors.
To determine whether different patterns of fat distribution (up-
per versus lower) are associated with differences in WAT LRP5
gene expression, we analyzed LRP5 mRNA levels in paired SC
abdominal and gluteal fat from 47 females recruited based on
WC (Table S7). A WCR 80 cm is a measure of central obesity,
with increased CVD risk in Europid women as defined by the In-
ternational Diabetes Federation (Alberti et al., 2005). LRP5 gene
expression was selectively lower in the gluteal depot of womenCell Mwith android obesity (WC R 80 cm) (Figure 1G). Furthermore,
in partial correlation analyses, gluteal (but not abdominal) LRP5
expression correlated negatively with upper-body fat accumula-
tion, systemic insulin resistance, andmarkers of inflammation af-
ter adjustment for age, BMI, and menopausal status (Table S8).
We conclude that reduced gluteal WAT LRP5 gene expression
correlates with upper-body fat accumulation and an adverse
metabolic and inflammatory profile.
LRP5 Knockdown Has Distinct Biological Effects
in Abdominal and Gluteal Progenitors
In light of our earlier findings, we investigated the role of LRP5 in
depot-specific adipose progenitor biology using an immortalized
pair of SC abdominal and gluteal SVCs. While displaying
enhanced proliferation and adipogenesis (our unpublished
data), these cells retain their depot-specific gene expression sig-
natures (Pinnick et al., 2014). Stable LRP5 knockdown (KD) in
these immortalized SVCswas achieved by lentiviral transduction
with two independent shRNAs (Figures 2A and S3A). Both
shRNAs targeted the two protein-coding LRP5 transcripts
(http://www.ensembl.org) and were specific to LRP5 as no
change in LRP6 mRNA levels was detected. The aim of these
experiments was to compare the biological effects of equivalent
LRP5 gene dosage reduction in abdominal and gluteal
SVCs rather than to completely silence LRP5. Clone
TRCN0000033400 (sh400) gave the more efficient KD. As in-
tended, the KD magnitude was equivalent in abdominal and
gluteal progenitors (see LRP5 gene expression panel in Fig-
ure 2A). Nonetheless, due to the higher LRP5 gene expression
in abdominal SVCs, the percentage KD achieved was 33% in
abdominal versus 73% in gluteal cells compared to scrambled
shRNA-transduced SVCs. Less efficient LRP5 gene silencing
(24% in abdominal versus 56% in gluteal SVCs) was achieved
with shRNA clone TRCN0000033401 (sh401); again, in absoluteetabolism 21, 262–272, February 3, 2015 ª2015 The Authors 265
Figure 2. LRP5 KD in Immortalized Abdominal and Gluteal SVCs Alters Cell Proliferation and Adipogenesis
(A) LRP5 KD was confirmed by qRT-PCR and western blot analyses. LRP6 mRNA expression was not altered by LRP5 KD. shCON, control; sh400, LRP5-KD
cells. **p < 0.01, ***p < 0.001. a-tubulin was used as a western blot loading control.
(B) Doubling time of shCON and sh400 abdominal and gluteal SVCs. *p < 0.05, **p < 0.01, shCON versus sh400; #p < 0.05, Abdo-sh400 versus Glut-sh400.
(C) Representative micrographs of shCON and sh400 abdominal and gluteal SVCs at day 14 of adipogenic differentiation and histogram showing relative lipid
accumulation, assessed by AdipoRed staining (n = 42 wells/group). ***p < 0.001.
(D and E) Relative mRNA levels of adipogenic genes CEBPA, FABP4, and PPARG2 in (D) abdominal and (E) gluteal cells at baseline (d0) and day 14 (d14) of
adipogenic differentiation. shCON versus sh400 cells: #p < 0.01; d0 versus d14 cells: ap < 0.05, bp < 0.01. Histogram data are means ± SEM. qRT-PCR data were
normalized to 18S. n = 5–7 independent experiments. See also Figures S1, S3, and S4.terms LRP5 KDwas near-identical in abdominal and gluteal cells
(Figure S3A). LRP5 KD using either shRNA was associated with
impaired proliferation in both abdominal and gluteal SVCs (Fig-
ure 2B and our unpublished data), a finding confirmed by LRP5
KD in primary SVCs derived from a female subject (Figure S4A).
Decreased LRP5 expression in gluteal cells was also associated
with a marked and dose-dependent inhibition of differentiation
as ascertained by lipid accumulation and adipogenic gene
expression (Figures 2C, 2E, S3B, and S3D). LRP5-KD gluteal ad-
ipocytes further exhibited heightened inflammation as deter-
mined by increased IL6 and MCP1 transcript levels (Figures
S1B and S1C). In contrast, LRP5 KD in abdominal progenitors
using sh400 was not associated with changes in adipogenesis
or adipocyte inflammation (Figures 2C, 2D, and S1B); more strik-266 Cell Metabolism 21, 262–272, February 3, 2015 ª2015 The Authoingly, stable expression of sh401 in abdominal SVCs led to
enhanced differentiation (Figures S3B and S3C). Similar effects
on adipogenesis were observed following sh400-mediated
LRP5 KD in female primary adipose SVCs (Figure S4B). In sum-
mary, equivalent absolute KD of LRP5 in abdominal and gluteal
progenitors leads to distinct biological outcomes that may be
driven by the differential LRP5 gene expression between the
two progenitor populations.
LRP5 KD Dose-Dependently Impairs Canonical WNT
Signaling in Adipose Progenitors
We examined which WNT pathway(s) were responsible for the
biological actions of LRP5. LRP5 KD in both abdominal and
gluteal cells led to impaired canonical WNT signaling, asrs
Figure 3. Effect of LRP5 KD on Canonical and Non-Canonical WNT and Insulin Signaling Pathways in Abdominal and Gluteal SVCs
(A) Western blots for pLRP5/6-Ser1490, active b-catenin, pJNK, and pCAMK2A and qRT-PCR analyses of AXIN2 and IL6, in control (shCON) and LRP5-KD
(sh400) abdominal and gluteal immortalized SVCs. a-tubulin, total-JNK (tJNK), and total CAMK2A (tCAMK2A) were western blot loading controls. *p < 0.05,
**p < 0.01.
(B) Representative western blots of shCON and sh400 abdominal and gluteal immortalized SVCs stimulated with 100 nM insulin for indicated duration. *non-
specific band, used as loading control.
(C) INSR mRNA levels in shCON and sh400 abdominal and gluteal immortalized SVCs.
(D) Representative western blots of shCON and sh400 abdominal and gluteal primary (1) SVCs stimulated with 10 nM insulin for indicated duration. *non-specific
band detectedwith anti-pIRS1 (Y612) rabbit pAb, **non-specific band detected with anti-LRP5 rabbit mAb, used as loading controls. Histogramdata aremeans ±
SEM. n = 5–7 independent experiments. qRT-PCR data were normalized to 18S. See also Figure S3.determined by decreased active b-catenin and phosphorylated
(active) LRP5/6 protein levels and reduced expression of
AXIN2, a universal b-catenin target gene (Figures 3A and S3E).
Given that b-catenin is generally thought to restrain adipogene-
sis, these findings are prima facie counterintuitive to the block
in differentiation seen in gluteal SVCs. We next examined
whether non-canonical WNT pathways were differentially regu-
lated following LRP5 KD in abdominal and gluteal progenitors.
However, both PCP and WNT/Ca2+ signaling were modulated
in a directionally uniform manner in LRP5-KD cells. Specifically,
LRP5 KD using sh400 (i.e., the more efficient shRNA) led to
increased JNK phosphorylation and elevated IL6 expression in
both abdominal and gluteal SVCs, consistent with PCP pathway
activation (Figure 3A). Conversely, the phosphorylated to total
CAMK2A ratio was uniformly decreased in abdominal and
gluteal LRP5-KD cells (Figures 3A, S3E, and S3F). LRP5 was
shown to promote insulin signaling and adipogenesis in 3T3-L1
preadipocytes (Palsgaard et al., 2012). Hence, we asked
whether insulin/IGF1 signaling was driving the actions of LRP5
on adipose progenitor biology. As shown in Figures 3B and
S3G, however, neither basal nor stimulated phosphorylation ofCell MIRS1, AKT, or ERK1/2 following treatment with 100 nM insulin
(i.e., the same dose used to induce adipogenesis) were altered
with LRP5 KD. Consistent with these data, no baseline change
in insulin receptor (INSR) gene expression was detected in
response to LRP5 KD in either abdominal or gluteal SVCs (Fig-
ures 3C and S3H). We confirmed and extended these findings
in LRP5-KD primary SVCs treated with a more physiological in-
sulin dose (10 nM) (Figure 3D).
b-catenin has been shown to dose-dependently modulate
target gene expression and stem/progenitor cell cycling and
fate-determination (Hirata et al., 2013; Kielman et al., 2002;
Luis et al., 2011). Given the graded effects of LRP5 KD on
abdominal and gluteal SVC proliferation and differentiation, we
examined whether active b-catenin levels and b-catenin target
genes were regulated in a dose-like fashion. This was indeed
the case (Figures 4A and 4B). Mirroring these findings, selec-
tively attenuating b-catenin transcriptional activity with use of
the small-molecule inhibitor iCRT14 (Gonsalves et al., 2011)
dose-dependently impaired adipogenesis in immortalized
gluteal SVCs (Figure 4C). In contrast, low-dose iCTR14 (1 mM)
enhanced adipogenesis in abdominal progenitors while higheretabolism 21, 262–272, February 3, 2015 ª2015 The Authors 267
Figure 4. LRP5-KD in Abdominal and Gluteal SVCs Dose-Dependently Modulates b-Catenin Signaling
(A) Protein densitometry of LRP5, pLRP5/6-S1490, and active b-catenin in Abdo-sh401, Abdo-sh400, Glut-sh401, andGlut-sh400 SVCs. Densitometry data were
normalized to a-tubulin and are shown relative to their respective shCON levels. n = 3–4 independent experiments.
(B) Gene expression profiling of b-catenin target genes in Abdo-sh401, Abdo-sh400, Glut-sh401, and Glut-sh400 SVCs. mRNA data were normalized to 18S and
are shown relative to their respective shCON levels. n = 4–7 independent experiments.
(C) Treatment with the b-catenin small-molecule inhibitor iCRT14 dose-dependently modulates TOPflash promoter activity, adipogenesis, and proliferation in
immortalized abdominal and gluteal SVCs (n = 6–7 replicates). Histogram data are means ± SEM. *,#p < 0.05, **,##p < 0.01, ***p < 0.001. *,**,*** within group
comparisons; #,## between group comparisons.dose (10 mM) impaired differentiation, albeit to a lesser extent
than the equivalent dose in gluteal cells. Accordingly, iCTR14-
induced inhibition of b-catenin-dependent promoter activity
was more pronounced in gluteal than abdominal SVCs. iCRT14
also dose-dependently impaired adipose progenitor prolifera-
tion. As expected, this effect was more marked in gluteal versus
abdominal cells (Figure 4C). We conclude that the biological ef-
fects of LRP5 KD in adipose progenitors are driven by dose-268 Cell Metabolism 21, 262–272, February 3, 2015 ª2015 The Authodependent reductions in b-catenin transcriptional activity,
which, for an equivalent decrease in LRP5 gene dosage, is
more potently blocked in gluteal than abdominal SVCs.
DISCUSSION
Fat distribution is a heritable trait that strongly predicts diabetes
and CVD risk independent of obesity. In this study we identify thers
WNT co-receptor LRP5 as a regulator of adipose progenitor
biology and regional adiposity. By examining three HBM pedi-
grees, we show that rare GoF LRP5 mutations are associated
with an increased amount of lower-body fat. Complimentary to
these findings we also demonstrate, through the analysis of
DXA data from > 3,000 individuals, that theminor allele of a com-
mon SNP in LRP5 associated with low BMD correlates with
modestly increased upper-body fat accumulation. From the di-
rection of its effect upon BMD, this allele is likely to be associated
with reduced LRP5 function. Based on our in vitro KD studies,
the increased central adiposity observed in rs599083minor allele
carriers is likely to be driven by enhanced cellularity of the SC
abdominal relative to the gluteofemoral fat depot. Nonetheless,
in these same experiments, LRP5-KD SC abdominal SVCs ex-
hibited impaired proliferation and enhanced inflammation. We
speculate that this is likely to impact negatively on the size and
quality of the SVC pool and ultimately adipocyte number in this
depot, too, a hypothesis consistent with the histological analysis
of SC abdominal WAT from a limited number of rs599083 minor
versus homozygous major allele carriers (Figures S2B and S2C).
LRP5 HBM individuals also exhibited enhanced insulin sensi-
tivity versus age-, gender-, and BMI-matched controls. This may
be at least partly due to their more favorable body fat distribution
coupled with greater WAT cellularity (i.e., fat storage capacity,
thought to protect against ectopic lipid deposition and lipotoxic-
ity) due to enhanced SVC proliferation and, in the case of gluteal
SVCs, potentially also differentiation. In contrast, rs599083 was
not associated with T2D risk ormeasures of BMI-adjusted insulin
sensitivity in publically available data sets from the DIAGRAM
(Morris et al., 2012) and MAGIC (Manning et al., 2012) consortia,
respectively. However, power to detect phenotypic associations
between WHR- and BMI-associated variants and related meta-
bolic parameters can be low. Accordingly, not all signals associ-
ated with fat distribution showed significant associations with
surrogates of insulin resistance in the meta-analysis by Heid
et al. (Heid et al., 2010). This is likely due to the limited power
to detect downstream phenotypes, given the relatively low effect
sizes at individual loci, even when the overall phenotypic associ-
ations are strong.
The lack of and weak association between rs599083 and
anthropometric measures of fat distribution in the OBB (Table
S4) and GIANT data sets, respectively, is notable. In this regard
we detected only modest age-, gender-, and BMI-adjusted cor-
relations between anthropometric and DXA-derivedmeasures of
fat distribution within the OBB (Table S5). Furthermore, alter-
ations in body shape and/or skeletal geometry consequent to
the actions of LRP5 on bone may mask the associations be-
tween LRP5 variants and anthropometric surrogates of
adiposity. In keeping with this, rs3736228, a non-synonymous
exonic SNP in LRP5 that is in linkage disequilibrium with
rs599083, was shown to modulate femoral neck width, femoral
shaft geometry, and vertebral body size (Boudin et al., 2013;
van Meurs et al., 2006). Moreover, in a study of 258 individuals
with unexplained HBM, HBM cases had significantly broader
skeletal frames compared with controls (Gregson et al., 2012).
Accordingly, we detected no consistent differences in anthropo-
metric measures of fat distribution between HBM LRP5mutation
carriers and matched OBB controls (Table S2). Finally, distinct
from the WAT expression pattern of LRP5, RSPO3 (Figure 1C)Cell Mand ZNRF3 (Schleinitz et al., 2014) are more highly expressed
in visceral versus SC fat. These contrasting gene expression pro-
files may also account for the more robust association between
SNPs within these genes and body fat distribution in GWAS.
Much of the impetus for this work was based on an earlier
search for WNT pathway genes that were differentially ex-
pressed between SC abdominal and gluteal SVCs. We had
reasoned that these may underlie intrinsic differences in WNT
pathway tone (signal strength) and/or specificity (canonical
versus non-canonical pathway activation) between abdominal
and gluteal progenitors. Such changes in turn might endow
SVCs from these depots with distinct functional properties,
thereby driving changes in fat distribution. As part of those ana-
lyses, LRP5was found to bemore highly expressed in abdominal
versus gluteal progenitors. Herein we show that, consistent with
our original hypothesis, equivalent magnitude of LRP5 KD in
abdominal and gluteal SVCs leads to markedly different propor-
tional reduction in LRP5 levels/activity and distinct biological
outcomes; LRP5 KD impaired proliferation to a greater extent
in immortalized gluteal than abdominal progenitors (Figure 2B).
Furthermore, while LRP5 KD in gluteal SVCs led to impaired adi-
pogenesis, differentiation in abdominal cells was unchanged and
even enhanced following modest and low-level LRP5 KD,
respectively. Finally, compared with controls, gluteal but not
abdominal LRP5-KD adipocytes were inflamed. We speculate
that by modulating regional WAT cellularity, these diverse bio-
logical responses underlie, at least partly, the effects of LRP5
on fat distribution. Moreover, they are rooted in the different
levels of LRP5 expression between abdominal and gluteal
progenitors coupled with dose-dependent effects of LRP5 on
SVC function. As such, due to the lower LRP5 transcript and pro-
tein levels in gluteal versus abdominal SVCs (Figures 1D and 1E),
gluteal progenitors are likely to bemore sensitive than abdominal
progenitors to changes in (1) LRP5 function, due to missense
variants, and (2) LRP5mRNA levels, e.g., decreased expression
driven by obesity or intronic SNPs. In agreement with this hy-
pothesis, we found that LRP5 gene expression in gluteal but
not SC abdominal WAT correlated negatively with upper-body
fat accumulation in females (Table S8). Adipocyte size (an in-
verse correlate of WAT cellularity) has also been reported to be
larger in the gluteal versus abdominal depot of women (Votruba
and Jensen, 2007). Complicating the interpretation of this
latter finding, however, hormonal signals—e.g., sex-steroids—
can interact with WNT signaling tone in vivo to modulate adipo-
cyte size (Elbers et al., 1999). Additionally, in weight-gaining
adults, abdominal WAT is thought to expand by hypertrophy
(Spalding et al., 2008; Tchoukalova et al., 2010) and gluteofe-
moral WAT by hyperplasia (Tchoukalova et al., 2010).
Mechanistically, the effects of LRP5 KD on SVC proliferation
arise from inhibition of canonical WNT signaling. This conclusion
was confirmed by the dose-dependent decrease in both b-cate-
nin-driven promoter activity and proliferation in adipose SVCs
following treatment with iCTR14. Furthermore, the link between
adipose cell inflammation and WNT/LRP5 signaling is likely to
have its basis in the mutually antagonistic actions of the b-cate-
nin and PCP pathways (Grumolato et al., 2010). Thus, suppress-
ing canonical WNT signaling promotes JNK activation, thereby
driving inflammation. Likewise, the enhanced differentiation
seen in abdominal cells following low-level LRP5-KD is inetabolism 21, 262–272, February 3, 2015 ª2015 The Authors 269
keeping with the well-established anti-adipogenic action of
WNT/b-catenin signaling. In contrast, further reduction in LRP5
levels progressively restrains adipocyte differentiation. In line
with this, LRP5-KD gluteal SVCs, which exhibit the lowest
LRP5 protein levels, display a ‘‘paradoxical’’ block in adipogen-
esis. The anti-adipogenic actions of LRP5 deficiency are not
mediated via altered non-canonical WNT signaling, as neither
the PCP nor the WNT/Ca2+ pathways were differentially modu-
lated in abdominal versus gluteal LRP5-KD cells. Moreover, in
contrast to Palsgaard et al. (Palsgaard et al., 2012), we were un-
able to detect any changes in insulin/IGF1 pathway activity in
response to LRP5 KD (Figures 3B and S3G). Instead, utilizing
iCRT14, we demonstrate that the anti-adipogenic effect of
LRP5 deficiency is likely to be driven by impaired b-catenin tran-
scriptional activity (Figure 4C). We note that we have not corrob-
orated this conclusion by rescuing adipogenesis in LRP5-KD
gluteal SVCs through augmenting b-catenin signaling. Such a
rescue experiment, however, is technically challenging, since
constitutively increasing b-catenin activity in adipose progeni-
tors potently blocks adipogenesis (Christodoulides et al.,
2009). Hence, rescuing differentiation in LRP5-KD gluteal cells
would require precisely titrating the degree as well as the timing
and duration of b-catenin signaling activation prior to and/or dur-
ing differentiation. Our results suggest that, similar to its mode of
action in stem/progenitor cells from other organs/tissues (Hirata
et al., 2013; Kielman et al., 2002; Luis et al., 2011), canonical
WNT signaling in human adipose SVCs is more complex than
an on/off switch. Rather, it is associated with different biological
outcomes dependent on a gradient of b-catenin transcriptional
activity. Finally, in conjunction with earlier findings (Donati
et al., 2014; Ross et al., 2000), our data also show that autono-
mous as well as non-autonomous WNT/b-catenin signals can
both promote and inhibit adipogenesis.
In summary, we have established that LRP5 acts by titrating
b-catenin signal strength tomodulate adipose progenitor biology
in a depot-specific manner, thus promoting lower-body fat accu-
mulation. Rational manipulation of LRP5 expression/activity to
achieve a more beneficial pattern of fat distribution may offer a
potential approach to treat obesity-associated CVD. We note
in this respect that treatment with humanized antibodies against
SOST (a secreted LRP5 antagonist) is currently in phase III trials
for osteoporosis management (McClung and Grauer, 2014).
Once such treatments become the mainstay for osteoporosis,
it will be important to determine their effects on fat distribution
and metabolic health.
EXPERIMENTAL PROCEDURES
Study Population and Sample Collection
Control study subjects were recruited from the OBB, a population-based
collection of healthy subjects aged 30–50 years (http://www.oxfordbiobank.
org.uk). HBM LRP5 mutation carriers were recruited from the UK-based
HBM study cohort (Gregson et al., 2012) (see Supplemental Information).
Paired SC abdominal and gluteal WAT specimens were obtained by needle bi-
opsy as described (McQuaid et al., 2011). Paired SC abdominal and visceral
fat samples were obtained from patients undergoing elective surgery as part
of the MolSURG study. All studies were approved by the Oxfordshire Clinical
Research Ethics Committee and the Bath multi-centre Research Ethics Com-
mittee, and all volunteers gave written, informed consent. Other aspects of the
study in pre- and post-menopausal women have previously been reported
(Hodson et al., 2014).270 Cell Metabolism 21, 262–272, February 3, 2015 ª2015 The AuthoDual Energy X-Ray Absorptiometry
Whole-body DXAs were performed using a Lunar iDXA (GE Healthcare).
Acquired images were processed using enCORE v14.1 software. Central-to-
peripheral fat ratio was calculated as android fat (g)O (arms + legs) fat (g).
Isolation, Culture, and Differentiation of Human SVCs
SVCs were isolated from WAT biopsies, cultured, and differentiated as
described (Collins et al., 2010) (see Supplemental Information). SVCs isolated
from a male subject were immortalized by co-expressing human telomerase
reverse transcriptase and human papillomavirus type-16 E7 oncoprotein (Pin-
nick et al., 2014). To study the effects of iCRT14 (Sigma-Aldrich) on adipogen-
esis, SVCs were seeded in type I collagen-coated 96-well plates. Culture
media were replaced after 24 hr with growth media containing iCRT14 (1 mM
or 10 mM) or DMSO. Confluent cells were differentiated 48 hr later in the
same concentration of iCRT14 (or DMSO) throughout for 21 days. Media
were changed every 2–3 days. Intracellular lipid levels were quantified using
the AdipoRed assay reagent (Lonza) and a CytoFluor Multi-Well Plate Reader
series 4000 (PerSeptive Biosystems).
Estimation of Cell Doubling Time
Equal numbers of control and LRP5-KD SVCs, i.e., 400,000 or 150,000, were
seeded in T175 and T75 flasks, respectively. Cells were trypsinized and double
counted every 72 hr. Doubling time was calculated using the formula Td = (t2
t1) 3 [log(2)O log(q2O q1)], where t = time (days) and q = cell number.
Lentiviral Constructs and Generation of Stable Cell Lines
MISSION LRP5 shRNA and control plasmid DNA vectors were obtained from
Sigma-Aldrich. The 7TFP WNT reporter lentiviral vector (Fuerer and Nusse,
2010) was obtained from Addgene. Lentiviral particles were produced by tran-
sient co-transfection of HEK293 cells with the vector of interest and packaging
vectors (MISSION [Sigma-Aldrich] and ViraPower [Invitrogen] packaging
mixes). Stable cell lines were generated by transduction of SVCs with lentiviral
particles followed by selection in growth media containing 2 mg/ml puromycin.
Insulin Stimulation Studies of SVCs
Stimulation experiments with 10 nM or 100 nM insulin (Sigma-Aldrich) were
performed as described (Palsgaard et al., 2012).
Genotyping, Quantitative Real-Time PCR, Western Blot Analyses,
and Measurement of Adipocyte Size and Number
Genotyping and qRT-PCR were performed using TaqMan assays. Western
blot analyses were performed using standard protocols. Adipocyte sizing
was performed using a histological method. Full details are found in Supple-
mental Information.
Luciferase Reporter Assay
Immortalized SVCs stably expressing 7TFP were grown to confluence in type I
collagen-coated 24-well plates in complete growth media, then treated with
indicated concentrations of iCRT14 (or DMSO) in serum-free media for
24 hr. Cell lysates were harvested in passive lysis buffer, and reporter activity
wasmeasured using the Luciferase Assay System (Promega) and a VeritasMi-
croplate Luminometer (Turner Biosystems). Data were normalized to protein
concentration.
Statistical Analysis
Statistical analyses for association studies between LRP5 SNPs and quantita-
tive traits were performed using the PLINK program v.1.07 (http://pngu.mgh.
harvard.edu/purcell/plink/) (Purcell et al., 2007). All quantitative traits were
log transformed and analyzed with a linear regression model. Data were
adjusted for age, gender, and BMI. Significance is presented as empirical p
values as calculated by the additional implementation of permutation proce-
dures (default under PLINK) to the linear regression model. For parametric
data, statistical significance was determined by pairwise comparisons using
a two-tailed paired or unpaired Student’s t test, as appropriate. For non-para-
metric data, group differences were determined using the Kruskal-Wallis one-
way analysis of variance. Statistical significance was determined by pairwise
comparisons using a two-tailed Mann-Whitney test. Statistical tests gener-
ating a p < 0.05 were considered significant. Partial correlations ofrs
non-parametric data were performed using the SPSS Statistics software
package and adjusted for age, gender, and BMI. For studies of the HBM
cohort, matched analyses used radius matching based on age, gender, and
BMI with a 3:1 ratio, using a multi-level regression model clustering by match
set. All data are presented as means ± SEM unless otherwise stated.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2015.01.009.
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